| 产品详情 |
| Edit |   |
|---|
| Product Name | XL-647 |
|---|
| Description | XL-647 is an orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. It binds to and inhibits several receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4). MW: 491.38. Purity ≥98% by HPLC |
|---|
| Size | 5 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-(((3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl)methoxy)quinazolin-4-amine; Tesevatinib; EXEL-7647; KD-019 |
|---|
| Gene, Accession, CAS # | CAS: 781613-23-8 |
|---|
| Catalog # | B2204-5 |
|---|
| Price | |
|---|
| Order / More Info | XL-647 from BIOVISION, INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|